Lizolid 600 Tablet contains Linezolid 600 mg, an oxazolidinone-class antibiotic indicated for the treatment of serious bacterial infections caused by susceptible Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). It is primarily utilized in managing complicated skin and soft tissue infections, nosocomial and community-acquired pneumonia, and infections caused by multidrug-resistant organisms. Linezolid exerts its bacteriostatic effect by inhibiting bacterial protein synthesis through binding to the 23S ribosomal RNA of the 50S subunit, thereby preventing the formation of the initiation complex. Lizolid 600 Tablet is administered orally, offering excellent bioavailability and tissue penetration. The recommended dosage and duration depend on the infection type and severity, typically ranging from 10 to 28 days. Caution is advised in patients with a history of myelosuppression, as Linezolid may cause reversible bone marrow suppression, thrombocytopenia, and anemia, particularly with prolonged use. Additionally, concurrent use with serotonergic agents requires careful monitoring due to the risk of serotonin syndrome. Common adverse effects include headache, diarrhea, nausea, and transient elevations in liver enzymes. Lizolid 600 Tablet should be used under strict medical supervision with appropriate microbiological guidance to ensure efficacy and minimize resistance development.